Chief Medical Officer Mythili Koneru resigns effective April 9, 2023

Marker Therapeutics, Inc.

Mythili Koneru notified Marker Therapeutics of her resignation as Chief Medical Officer, effective April 9, 2023.
No replacement or interim successor has been announced by the company.
The departure removes a key clinical oversight role from the biotech firm.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mythili Koneru

Chief Medical Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2023-04-09
Filed: March 16, 2023, 7:59 PM ET

On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc. (the “ Company ”), notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mythili Koneru resigned as Chief Medical Officer at Marker Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc. (the “ Company ”), notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.

View on SEC.gov

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-033300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.